$1.9M EBITDA MedTech Company - 2.3x EBITDA fixed entry multiple

Fixed entry multiple is 2.3x EBITDA ($4.3m cash on closing with a $7.0m contingent payment). Preferred equity: 10% preferred return and 2.0x step up. Strong operating team of sponsors will take over management from the 70 year old husband and wife founders. Closing date: April 30th, 2026.